ID   EGR2_HUMAN              Reviewed;         476 AA.
AC   P11161; B2R724; B3KRD7; Q68CZ5; Q8IV26; Q9UNA6;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2003, sequence version 3.
DT   28-JAN-2026, entry version 238.
DE   RecName: Full=E3 SUMO-protein ligase EGR2;
DE            EC=2.3.2.- {ECO:0000269|PubMed:21836637};
DE   AltName: Full=AT591;
DE   AltName: Full=E3 SUMO-protein transferase ERG2 {ECO:0000305};
DE   AltName: Full=Early growth response protein 2;
DE            Short=EGR-2;
DE   AltName: Full=Zinc finger protein Krox-20;
GN   Name=EGR2; Synonyms=KROX20;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RX   PubMed=3140236; DOI=10.1073/pnas.85.19.7164;
RA   Joseph L.J., le Beau M.M., Jamieson G.A. Jr., Acharya S., Shows T.B.,
RA   Rowley J.D., Sukhatme V.P.;
RT   "Molecular cloning, sequencing, and mapping of EGR2, a human early growth
RT   response gene encoding a protein with 'zinc-binding finger' structure.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7164-7168(1988).
RN   [2]
RP   ERRATUM OF PUBMED:3140236, AND SEQUENCE REVISION TO C-TERMINUS.
RA   Joseph L.J., le Beau M.M., Jamieson G.A. Jr., Acharya S., Shows T.B.,
RA   Rowley J.D., Sukhatme V.P.;
RL   Proc. Natl. Acad. Sci. U.S.A. 86:515-515(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), VARIANTS CHN1 ASN-268 AND
RP   382-SER-ASP-383 DELINS ARG-TYR, AND VARIANT CMT1D TRP-409.
RX   PubMed=9537424; DOI=10.1038/ng0498-382;
RA   Warner L.E., Mancias P., Butler I.J., McDonald C.M., Keppen L., Koob K.G.,
RA   Lupski J.R.;
RT   "Mutations in the early growth response 2 (EGR2) gene are associated with
RT   hereditary myelinopathies.";
RL   Nat. Genet. 18:382-384(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND SHORT).
RC   TISSUE=Brain, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21.
RX   PubMed=2111009; DOI=10.1093/nar/18.9.2749;
RA   Rangnekar V.M., Aplin A.C., Sukhatme V.P.;
RT   "The serum and TPA responsive promoter and intron-exon structure of EGR2, a
RT   human early growth response gene encoding a zinc finger protein.";
RL   Nucleic Acids Res. 18:2749-2757(1990).
RN   [10]
RP   INTERACTION WITH HCFC1, AND MUTAGENESIS OF 162-ASP--TYR-165.
RX   PubMed=14532282; DOI=10.1074/jbc.m303470200;
RA   Luciano R.L., Wilson A.C.;
RT   "HCF-1 functions as a coactivator for the zinc finger protein Krox20.";
RL   J. Biol. Chem. 278:51116-51124(2003).
RN   [11]
RP   INTERACTION WITH WWP2.
RX   PubMed=19651900; DOI=10.1128/mcb.00407-09;
RA   Chen A., Gao B., Zhang J., McEwen T., Ye S.Q., Zhang D., Fang D.;
RT   "The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell
RT   death by catalyzing EGR2 ubiquitination.";
RL   Mol. Cell. Biol. 29:5348-5356(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   FUNCTION AS SUMO LIGASE, CATALYTIC ACTIVITY, AND INTERACTION WITH UBC9.
RX   PubMed=21836637; DOI=10.1038/embor.2011.152;
RA   Garcia-Gutierrez P., Juarez-Vicente F., Gallardo-Chamizo F., Charnay P.,
RA   Garcia-Dominguez M.;
RT   "The transcription factor Krox20 is an E3 ligase that sumoylates its Nab
RT   coregulators.";
RL   EMBO Rep. 12:1018-1023(2011).
RN   [14]
RP   VARIANT CMT1D VAL-355.
RA   Di Maria E., Bellone E., Soriani S., Varese A., Lamba Doria L., Grandis M.,
RA   Schenone A., Levi G., Ajmar F., Mandich P.;
RT   "EGR2 gene mutation in a patient affected with Charcot-Marie-Tooth type
RT   1.";
RL   Eur. J. Hum. Genet. Suppl. 7:99-99(1999).
RN   [15]
RP   VARIANT CMT1D VAL-355.
RX   PubMed=10502832;
RX   DOI=10.1002/(sici)1098-1004(199910)14:4<353::aid-humu17>3.0.co;2-4;
RA   Bellone E., Di Maria E., Soriani S., Varese A., Lamba Doria L., Ajmar F.,
RA   Mandich P.;
RT   "A novel mutation (D305V) in the early growth response 2 gene is associated
RT   with severe Charcot-Marie-Tooth type 1 disease.";
RL   Hum. Mutat. 14:353-354(1999).
RN   [16]
RP   VARIANT DSS TRP-359.
RX   PubMed=10371530; DOI=10.1212/wnl.52.9.1827;
RA   Timmerman V., De Jonghe P., Ceuterick C., De Vriendt E., Lofgren A.,
RA   Nelis E., Warner L.E., Lupski J.R., Martin J.-J., Van Broeckhoven C.;
RT   "Novel missense mutation in the early growth response 2 gene associated
RT   with Dejerine-Sottas syndrome phenotype.";
RL   Neurology 52:1827-1832(1999).
RN   [17]
RP   VARIANT CMT1D HIS-381.
RX   PubMed=10762521; DOI=10.1212/wnl.54.8.1696;
RA   Pareyson D., Taroni F., Botti S., Morbin M., Baratta S., Lauria G.,
RA   Ciano C., Sghirlanzoni A.;
RT   "Cranial nerve involvement in CMT disease type 1 due to early growth
RT   response 2 gene mutation.";
RL   Neurology 54:1696-1698(2000).
RN   [18]
RP   VARIANT CMT1D CYS-381.
RX   PubMed=11239949; DOI=10.1016/s0022-510x(00)00504-9;
RA   Yoshihara T., Kanda F., Yamamoto M., Ishihara H., Misu K., Hattori N.,
RA   Chihara K., Sobue G.;
RT   "A novel missense mutation in the early growth response 2 gene associated
RT   with late-onset Charcot-Marie-Tooth disease type 1.";
RL   J. Neurol. Sci. 184:149-153(2001).
RN   [19]
RP   VARIANT CMT1D TYR-383.
RX   PubMed=12736090; DOI=10.1016/s0022-510x(03)00028-5;
RA   Numakura C., Shirahata E., Yamashita S., Kanai M., Kijima K., Matsuki T.,
RA   Hayasaka K.;
RT   "Screening of the early growth response 2 gene in Japanese patients with
RT   Charcot-Marie-Tooth disease type 1.";
RL   J. Neurol. Sci. 210:61-64(2003).
RN   [20]
RP   VARIANT CMT1D TRP-359.
RX   PubMed=15241803; DOI=10.1002/humu.9261;
RA   Choi B.-O., Lee M.S., Shin S.H., Hwang J.H., Choi K.-G., Kim W.-K.,
RA   Sunwoo I.N., Kim N.K., Chung K.W.;
RT   "Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-
RT   Marie-Tooth neuropathy patients.";
RL   Hum. Mutat. 24:185-186(2004).
RN   [21]
RP   VARIANT CMT1D TRP-359.
RX   PubMed=15947997; DOI=10.1007/s10048-005-0217-4;
RA   Chung K.W., Sunwoo I.N., Kim S.M., Park K.D., Kim W.-K., Kim T.S., Koo H.,
RA   Cho M., Lee J., Choi B.O.;
RT   "Two missense mutations of EGR2 R359W and GJB1 V136A in a Charcot-Marie-
RT   Tooth disease family.";
RL   Neurogenetics 6:159-163(2005).
RN   [22]
RP   VARIANT DSS LYS-412, CHARACTERIZATION OF VARIANTS CHN1 ASN-268,
RP   CHARACTERIZATION OF VARIANTS DSS TRP-359 AND LYS-412, CHARACTERIZATION OF
RP   VARIANTS CMT1D TRP-359, AND FUNCTION.
RX   PubMed=17717711; DOI=10.1007/s10048-007-0094-0;
RA   Szigeti K., Wiszniewski W., Saifi G.M., Sherman D.L., Sule N.,
RA   Adesina A.M., Mancias P., Papasozomenos S.C., Miller G., Keppen L.,
RA   Daentl D., Brophy P.J., Lupski J.R.;
RT   "Functional, histopathologic and natural history study of neuropathy
RT   associated with EGR2 mutations.";
RL   Neurogenetics 8:257-262(2007).
RN   [23]
RP   INVOLVEMENT IN CHN1.
RX   PubMed=22522483; DOI=10.1002/ana.23527;
RA   Funalot B., Topilko P., Arroyo M.A., Sefiani A., Hedley-Whyte E.T.,
RA   Yoldi M.E., Richard L., Touraille E., Laurichesse M., Khalifa E.,
RA   Chauzeix J., Ouedraogo A., Cros D., Magdelaine C., Sturtz F.G.,
RA   Urtizberea J.A., Charnay P., Bragado F.G., Vallat J.M.;
RT   "Homozygous deletion of an EGR2 enhancer in congenital amyelinating
RT   neuropathy.";
RL   Ann. Neurol. 71:719-723(2012).
RN   [24]
RP   VARIANT CMT1D ASN-387.
RX   PubMed=22734907; DOI=10.1111/j.1529-8027.2012.00403.x;
RA   Shiga K., Noto Y., Mizuta I., Hashiguchi A., Takashima H., Nakagawa M.;
RT   "A novel EGR2 mutation within a family with a mild demyelinating form of
RT   Charcot-Marie-Tooth disease.";
RL   J. Peripher. Nerv. Syst. 17:206-209(2012).
RN   [25]
RP   VARIANT CMT1D GLY-412.
RX   PubMed=22546699; DOI=10.1016/j.nmd.2012.04.002;
RA   Safka Brozkova D., Nevsimalova S., Mazanec R., Rautenstrauss B., Seeman P.;
RT   "Charcot-Marie-Tooth neuropathy due to a novel EGR2 gene mutation with mild
RT   phenotype--usefulness of human mapping chip linkage analysis in a Czech
RT   family.";
RL   Neuromuscul. Disord. 22:742-746(2012).
RN   [26]
RP   VARIANT CMT1D GLY-412, AND CHARACTERIZATION OF VARIANT CMT1D GLY-412.
RX   PubMed=30843326; DOI=10.1111/jns.12314;
RA   Tozza S., Magri S., Pennisi E.M., Schirinzi E., Pisciotta C.,
RA   Balistreri F., Severi D., Ricci G., Siciliano G., Taroni F., Santoro L.,
RA   Manganelli F.;
RT   "A novel family with axonal Charcot-Marie-Tooth disease caused by a
RT   mutation in the EGR2 gene.";
RL   J. Peripher. Nerv. Syst. 24:219-223(2019).
RN   [27]
RP   VARIANT DSS GLY-411.
RX   PubMed=31852952; DOI=10.1038/s41598-019-55875-4;
RA   Grosz B.R., Golovchenko N.B., Ellis M., Kumar K., Nicholson G.A.,
RA   Antonellis A., Kennerson M.L.;
RT   "A de novo EGR2 variant, c.1232A > G p.Asp411Gly, causes severe early-onset
RT   Charcot-Marie-Tooth Neuropathy Type 3 (Dejerine-Sottas Neuropathy).";
RL   Sci. Rep. 9:19336-19336(2019).
CC   -!- FUNCTION: Sequence-specific DNA-binding transcription factor
CC       (PubMed:17717711). Plays a role in hindbrain segmentation by regulating
CC       the expression of a subset of homeobox containing genes and in Schwann
CC       cell myelination by regulating the expression of genes involved in the
CC       formation and maintenance of myelin (By similarity). Binds to two EGR2-
CC       consensus sites EGR2A (5'-CTGTAGGAG-3') and EGR2B (5'-ATGTAGGTG-3') in
CC       the HOXB3 enhancer and promotes HOXB3 transcriptional activation (By
CC       similarity). Binds to specific DNA sites located in the promoter region
CC       of HOXA4, HOXB2 and ERBB2 (By similarity). Regulates hindbrain
CC       segmentation by controlling the expression of Hox genes, such as HOXA4,
CC       HOXB3 and HOXB2, and thereby specifying odd and even rhombomeres (By
CC       similarity). Promotes the expression of HOXB3 in the rhombomere r5 in
CC       the hindbrain (By similarity). Regulates myelination in the peripheral
CC       nervous system after birth, possibly by regulating the expression of
CC       myelin proteins, such as MPZ, and by promoting the differentiation of
CC       Schwann cells (By similarity). Involved in the development of the jaw
CC       openener musculature, probably by playing a role in its innervation
CC       through trigeminal motor neurons (By similarity). May play a role in
CC       adipogenesis, possibly by regulating the expression of CEBPB (By
CC       similarity). {ECO:0000250|UniProtKB:P08152,
CC       ECO:0000269|PubMed:17717711}.
CC   -!- FUNCTION: E3 SUMO-protein ligase helping SUMO1 conjugation to its
CC       coregulators NAB1 and NAB2, whose sumoylation down-regulates EGR2
CC       transcriptional activity. {ECO:0000269|PubMed:21836637}.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Interacts with HCFC1 (PubMed:14532282). Interacts with WWP2
CC       (PubMed:19651900). Interacts with UBC9 (PubMed:21836637). Interacts
CC       with CITED1 (By similarity). Interacts (via phosphorylated form) with
CC       SFN (By similarity). {ECO:0000250|UniProtKB:P08152,
CC       ECO:0000269|PubMed:14532282, ECO:0000269|PubMed:19651900,
CC       ECO:0000269|PubMed:21836637}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P08152}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P11161-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P11161-2; Sequence=VSP_006863;
CC   -!- PTM: Ubiquitinated by WWP2 leading to proteasomal degradation.
CC       {ECO:0000250|UniProtKB:P08152}.
CC   -!- PTM: Acetylated at Lys-247. May be deacetylated by HDAC6, HDAC10 or
CC       SIRT1. {ECO:0000250|UniProtKB:P08152}.
CC   -!- DISEASE: Neuropathy, congenital hypomyelinating, 1, autosomal recessive
CC       (CHN1) [MIM:605253]: A severe degenerating neuropathy that results from
CC       a congenital impairment in myelin formation. It is clinically
CC       characterized by early onset of hypotonia, areflexia, distal muscle
CC       weakness, and very slow nerve conduction velocities (as low as 3m/s).
CC       Some patients manifest nearly complete absence of spontaneous limb
CC       movements, respiratory distress at birth, and complete absence of
CC       myelin shown by electron microscopy of peripheral nerves.
CC       {ECO:0000269|PubMed:17717711, ECO:0000269|PubMed:22522483,
CC       ECO:0000269|PubMed:9537424}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. Patients affected by the
CC       amyelinating form carry a causative, homozygous deletion encompassing a
CC       myelin-specific enhancer of EGR2 (PubMed:22522483).
CC       {ECO:0000269|PubMed:22522483}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, demyelinating, type 1D (CMT1D)
CC       [MIM:607678]: A dominant demyelinating form of Charcot-Marie-Tooth
CC       disease, a disorder of the peripheral nervous system, characterized by
CC       progressive weakness and atrophy, initially of the peroneal muscles and
CC       later of the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited) and
CC       primary peripheral axonal neuropathies (CMT2). Demyelinating
CC       neuropathies are characterized by severely reduced nerve conduction
CC       velocities (less than 38 m/sec), segmental demyelination and
CC       remyelination with onion bulb formations on nerve biopsy, slowly
CC       progressive distal muscle atrophy and weakness, absent deep tendon
CC       reflexes, and hollow feet. {ECO:0000269|PubMed:10502832,
CC       ECO:0000269|PubMed:10762521, ECO:0000269|PubMed:11239949,
CC       ECO:0000269|PubMed:12736090, ECO:0000269|PubMed:15241803,
CC       ECO:0000269|PubMed:15947997, ECO:0000269|PubMed:17717711,
CC       ECO:0000269|PubMed:22546699, ECO:0000269|PubMed:22734907,
CC       ECO:0000269|PubMed:30843326, ECO:0000269|PubMed:9537424,
CC       ECO:0000269|Ref.14}. Note=The disease is caused by variants affecting
CC       the gene represented in this entry.
CC   -!- DISEASE: Dejerine-Sottas syndrome (DSS) [MIM:145900]: A severe
CC       degenerating neuropathy of the demyelinating Charcot-Marie-Tooth
CC       disease category, with onset by age 2 years. Characterized by motor and
CC       sensory neuropathy with very slow nerve conduction velocities,
CC       increased cerebrospinal fluid protein concentrations, hypertrophic
CC       nerve changes, delayed age of walking as well as areflexia. There are
CC       both autosomal dominant and autosomal recessive forms of Dejerine-
CC       Sottas syndrome. {ECO:0000269|PubMed:10371530,
CC       ECO:0000269|PubMed:17717711, ECO:0000269|PubMed:31852952}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the EGR C2H2-type zinc-finger protein family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52372.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAA52372.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Inherited peripheral neuropathies mutation db;
CC       URL="https://uantwerpen.vib.be/CMTMutations";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04076; AAA52372.1; ALT_SEQ; mRNA.
DR   EMBL; AF139463; AAD24588.1; -; mRNA.
DR   EMBL; AK091399; BAG52349.1; -; mRNA.
DR   EMBL; AK312813; BAG35671.1; -; mRNA.
DR   EMBL; CR749641; CAH18435.1; -; mRNA.
DR   EMBL; AL133417; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471083; EAW54238.1; -; Genomic_DNA.
DR   EMBL; CH471083; EAW54239.1; -; Genomic_DNA.
DR   EMBL; BC035625; AAH35625.1; -; mRNA.
DR   EMBL; X53700; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS44409.1; -. [P11161-2]
DR   CCDS; CCDS7267.1; -. [P11161-1]
DR   RefSeq; NP_000390.2; NM_000399.4. [P11161-1]
DR   RefSeq; NP_001129649.1; NM_001136177.3. [P11161-1]
DR   RefSeq; NP_001129650.1; NM_001136178.2. [P11161-1]
DR   RefSeq; NP_001129651.1; NM_001136179.3. [P11161-2]
DR   RefSeq; NP_001307966.1; NM_001321037.2. [P11161-2]
DR   RefSeq; XP_054220940.1; XM_054364965.1. [P11161-2]
DR   AlphaFoldDB; P11161; -.
DR   SMR; P11161; -.
DR   BioGRID; 108279; 164.
DR   FunCoup; P11161; 2091.
DR   IntAct; P11161; 12.
DR   MINT; P11161; -.
DR   STRING; 9606.ENSP00000242480; -.
DR   GlyCosmos; P11161; 13 sites, 2 glycans.
DR   GlyGen; P11161; 14 sites, 1 N-linked glycan (1 site), 2 O-linked glycans (13 sites).
DR   iPTMnet; P11161; -.
DR   PhosphoSitePlus; P11161; -.
DR   BioMuta; EGR2; -.
DR   DMDM; 33112654; -.
DR   MassIVE; P11161; -.
DR   PaxDb; 9606-ENSP00000242480; -.
DR   PeptideAtlas; P11161; -.
DR   ProteomicsDB; 52701; -. [P11161-1]
DR   ProteomicsDB; 52702; -. [P11161-2]
DR   Antibodypedia; 14464; 538 antibodies from 42 providers.
DR   DNASU; 1959; -.
DR   Ensembl; ENST00000242480.4; ENSP00000242480.3; ENSG00000122877.18. [P11161-1]
DR   Ensembl; ENST00000411732.4; ENSP00000387634.1; ENSG00000122877.18. [P11161-2]
DR   Ensembl; ENST00000637191.2; ENSP00000490154.2; ENSG00000122877.18. [P11161-1]
DR   GeneID; 1959; -.
DR   KEGG; hsa:1959; -.
DR   MANE-Select; ENST00000242480.4; ENSP00000242480.3; NM_000399.5; NP_000390.2.
DR   UCSC; uc001jmi.4; human. [P11161-1]
DR   AGR; HGNC:3239; -.
DR   ClinPGx; PA27674; -.
DR   CTD; 1959; -.
DR   DisGeNET; 1959; -.
DR   GeneCards; EGR2; -.
DR   GeneReviews; EGR2; -.
DR   HGNC; HGNC:3239; EGR2.
DR   HPA; ENSG00000122877; Tissue enhanced (epididymis, thyroid gland).
DR   MalaCards; EGR2; -.
DR   MIM; 129010; gene.
DR   MIM; 145900; phenotype.
DR   MIM; 605253; phenotype.
DR   MIM; 607678; phenotype.
DR   OpenTargets; ENSG00000122877; -.
DR   Orphanet; 101084; Charcot-Marie-Tooth disease type 1D.
DR   Orphanet; 99951; Charcot-Marie-Tooth disease type 4E.
DR   Orphanet; 64748; Dejerine-Sottas syndrome.
DR   VEuPathDB; HostDB:ENSG00000122877; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000158394; -.
DR   HOGENOM; CLU_043235_0_0_1; -.
DR   InParanoid; P11161; -.
DR   OMA; QCQRELH; -.
DR   OrthoDB; 8197458at2759; -.
DR   PAN-GO; P11161; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; P11161; -.
DR   PathwayCommons; P11161; -.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-9031628; NGF-stimulated transcription.
DR   Reactome; R-HSA-9619665; EGR2 and SOX10-mediated initiation of Schwann cell myelination.
DR   SignaLink; P11161; -.
DR   SIGNOR; P11161; -.
DR   UniPathway; UPA00886; -.
DR   Agora; ENSG00000122877; -.
DR   BioGRID-ORCS; 1959; 230 hits in 1165 CRISPR screens.
DR   GeneWiki; EGR2; -.
DR   GenomeRNAi; 1959; -.
DR   Pharos; P11161; Tbio.
DR   PRO; PR:P11161; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P11161; protein.
DR   Bgee; ENSG00000122877; Expressed in gall bladder and 109 other cell types or tissues.
DR   ExpressionAtlas; P11161; baseline and differential.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0061665; F:SUMO ligase activity; ISS:ARUK-UCL.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035904; P:aorta development; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; TAS:ProtInc.
DR   GO; GO:0035284; P:brain segmentation; IEA:Ensembl.
DR   GO; GO:0021612; P:facial nerve structural organization; ISS:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0007422; P:peripheral nervous system development; TAS:ProtInc.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0031643; P:positive regulation of myelination; ISS:UniProtKB.
DR   GO; GO:0014040; P:positive regulation of Schwann cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006611; P:protein export from nucleus; ISS:UniProtKB.
DR   GO; GO:0016925; P:protein sumoylation; ISS:ARUK-UCL.
DR   GO; GO:0030278; P:regulation of ossification; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0021660; P:rhombomere 3 formation; IEA:Ensembl.
DR   GO; GO:0021659; P:rhombomere 3 structural organization; ISS:UniProtKB.
DR   GO; GO:0021666; P:rhombomere 5 formation; IEA:Ensembl.
DR   GO; GO:0021665; P:rhombomere 5 structural organization; ISS:UniProtKB.
DR   GO; GO:0007622; P:rhythmic behavior; IEA:Ensembl.
DR   GO; GO:0014037; P:Schwann cell differentiation; ISS:UniProtKB.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; ISS:UniProtKB.
DR   FunFam; 3.30.160.60:FF:000837; E3 SUMO-protein ligase EGR2 isoform X1; 1.
DR   FunFam; 3.30.160.60:FF:000324; Early growth response protein 4; 1.
DR   FunFam; 3.30.160.60:FF:000419; Early growth response protein 4; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 3.
DR   InterPro; IPR021849; EGR_N.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR23235:SF54; E3 SUMO-PROTEIN LIGASE EGR2; 1.
DR   PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1.
DR   Pfam; PF11928; DUF3446; 1.
DR   Pfam; PF00096; zf-C2H2; 3.
DR   SMART; SM00355; ZnF_C2H2; 3.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Alternative splicing; Charcot-Marie-Tooth disease;
KW   Dejerine-Sottas syndrome; Disease variant; DNA-binding; Metal-binding;
KW   Neurodegeneration; Neuropathy; Nucleus; Proteomics identification;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..476
FT                   /note="E3 SUMO-protein ligase EGR2"
FT                   /id="PRO_0000047119"
FT   ZN_FING         340..364
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         370..392
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         398..420
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          127..178
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          275..300
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          318..341
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          412..476
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           162..165
FT                   /note="HCFC1-binding-motif (HBM)"
FT   COMPBIAS        127..141
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        281..290
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        415..425
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        429..476
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         247
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000250|UniProtKB:P08152"
FT   VAR_SEQ         1..50
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_006863"
FT   VARIANT         268
FT                   /note="I -> N (in CHN1; loss of large and small myelinated
FT                   nerve fibers; dbSNP:rs104894158)"
FT                   /evidence="ECO:0000269|PubMed:17717711,
FT                   ECO:0000269|PubMed:9537424"
FT                   /id="VAR_007735"
FT   VARIANT         355
FT                   /note="D -> V (in CMT1D; dbSNP:rs1589080611)"
FT                   /evidence="ECO:0000269|PubMed:10502832, ECO:0000269|Ref.14"
FT                   /id="VAR_007736"
FT   VARIANT         359
FT                   /note="R -> W (in DSS and CMT1D; loss of DNA binding and
FT                   loss of transactivation activity; loss of small and large
FT                   myelinated nerve fibers; residual fibers with thin myelin
FT                   sheaths; dbSNP:rs104894161)"
FT                   /evidence="ECO:0000269|PubMed:10371530,
FT                   ECO:0000269|PubMed:15241803, ECO:0000269|PubMed:15947997,
FT                   ECO:0000269|PubMed:17717711"
FT                   /id="VAR_009874"
FT   VARIANT         381
FT                   /note="R -> C (in CMT1D; dbSNP:rs1589080524)"
FT                   /evidence="ECO:0000269|PubMed:11239949"
FT                   /id="VAR_029958"
FT   VARIANT         381
FT                   /note="R -> H (in CMT1D; dbSNP:rs281865137)"
FT                   /evidence="ECO:0000269|PubMed:10762521"
FT                   /id="VAR_009875"
FT   VARIANT         382..383
FT                   /note="SD -> RY (in CHN1)"
FT                   /evidence="ECO:0000269|PubMed:9537424"
FT                   /id="VAR_007737"
FT   VARIANT         383
FT                   /note="D -> Y (in CMT1D; dbSNP:rs104894160)"
FT                   /evidence="ECO:0000269|PubMed:12736090"
FT                   /id="VAR_029959"
FT   VARIANT         387
FT                   /note="T -> N (in CMT1D; uncertain significance;
FT                   dbSNP:rs281865139)"
FT                   /evidence="ECO:0000269|PubMed:22734907"
FT                   /id="VAR_083343"
FT   VARIANT         409
FT                   /note="R -> W (in CMT1D; dbSNP:rs104894159)"
FT                   /evidence="ECO:0000269|PubMed:9537424"
FT                   /id="VAR_007738"
FT   VARIANT         411
FT                   /note="D -> G (in DSS)"
FT                   /evidence="ECO:0000269|PubMed:31852952"
FT                   /id="VAR_083344"
FT   VARIANT         412
FT                   /note="E -> G (in CMT1D; loss of myelinated and
FT                   unmyelinated nerve fibers; dbSNP:rs749558026)"
FT                   /evidence="ECO:0000269|PubMed:22546699,
FT                   ECO:0000269|PubMed:30843326"
FT                   /id="VAR_083345"
FT   VARIANT         412
FT                   /note="E -> K (in DSS; loss of DNA binding and loss of
FT                   transactivation activity; dbSNP:rs121434563)"
FT                   /evidence="ECO:0000269|PubMed:17717711"
FT                   /id="VAR_083346"
FT   MUTAGEN         162..165
FT                   /note="DHLY->AAAA: Inhibits association with HCFC1."
FT                   /evidence="ECO:0000269|PubMed:14532282"
FT   CONFLICT        68
FT                   /note="K -> R (in Ref. 5; CAH18435)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="K -> KPFPCPLDTLRVPPPLTPLSTIRK (in Ref. 8; AAH35625)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        280
FT                   /note="V -> M (in Ref. 1; AAA52372)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   476 AA;  50302 MW;  7810D1B1B418DF1F CRC64;
     MMTAKAVDKI PVTLSGFVHQ LSDNIYPVED LAATSVTIFP NAELGGPFDQ MNGVAGDGMI
     NIDMTGEKRS LDLPYPSSFA PVSAPRNQTF TYMGKFSIDP QYPGASCYPE GIINIVSAGI
     LQGVTSPAST TASSSVTSAS PNPLATGPLG VCTMSQTQPD LDHLYSPPPP PPPYSGCAGD
     LYQDPSAFLS AATTSTSSSL AYPPPPSYPS PKPATDPGLF PMIPDYPGFF PSQCQRDLHG
     TAGPDRKPFP CPLDTLRVPP PLTPLSTIRN FTLGGPSAGV TGPGASGGSE GPRLPGSSSA
     AAAAAAAAAY NPHHLPLRPI LRPRKYPNRP SKTPVHERPY PCPAEGCDRR FSRSDELTRH
     IRIHTGHKPF QCRICMRNFS RSDHLTTHIR THTGEKPFAC DYCGRKFARS DERKRHTKIH
     LRQKERKSSA PSASVPAPST ASCSGGVQPG GTLCSSNSSS LGGGPLAPCS SRTRTP
//
